Abstract: Interlacing equipment may be used to form fabric and to create a gap in the fabric. The fabric may include one or more conductive strands. An insertion tool may be used to align an electrical component with the conductive strands during interlacing operations. A soldering tool may be used to remove insulation from the conductive strands to expose conductive segments on the conductive strands. The soldering tool may be used to solder the conductive segments to the electrical component. The solder connections may be located in grooves in the electrical component. An encapsulation tool may dispense encapsulation material in the grooves to encapsulate the solder connections. After the electrical component is electrically connected to the conductive strands, the insertion tool may position and release the electrical component in the gap. A component retention tool may temporarily be used to retain the electrical component in the gap as interlacing operations continue.

Abstract: Interlacing equipment may be used to form fabric and to create a gap in the fabric. The fabric may include one or more conductive strands. An insertion tool may be used to align an electrical component with the conductive strands during interlacing operations. A soldering tool may be used to remove insulation from the conductive strands to expose conductive segments on the conductive strands. The soldering tool may be used to solder the conductive segments to the electrical component. The solder connections may be located in grooves in the electrical component. An encapsulation tool may dispense encapsulation material in the grooves to encapsulate the solder connections. After the electrical component is electrically connected to the conductive strands, the insertion tool may position and release the electrical component in the gap. A component retention tool may temporarily be used to retain the electrical component in the gap as interlacing operations continue.

Abstract: A computer-implemented method for scanning data including accessing a reference table including a grid of data cells arranged in columns and rows and containing reference data elements. Each of the rows may relate to one of a plurality of data subjects. The method may also include generating a list of reference subcombinations. The list of reference subcombinations may be generated by designating a primary column for uniquely identifying the data subjects and generating a plurality of first preliminary reference subcombinations. Each of the first preliminary reference subcombinations may include reference data elements gathered from the primary column and a second column of a single row of the reference table. The method may also include accessing a subject file having a plurality of data entries. Each of the data entries may include a plurality of logically-related and delimited subject data elements.

Abstract: In one implementation, a computer-implemented method includes receiving, at a computer system, a request to solicit one or more users to generate media content for a campaign; identifying, by the computer system, a plurality of content creating users; obtaining demographic data for a plurality of content consuming users who have accessed the media content that was generated by the plurality of content creating users; determining distributions of the plurality of content consuming users across a plurality of demographic categories; selecting, by the computer system, a portion of the plurality of content creating users based on a comparison of i) the one or more parameters for the campaign and ii) the distributions of the plurality of content consuming users across the plurality of demographic categories; and providing information that identifies an opportunity to generate media content for the campaign.

Abstract: Implementations for providing a persistent secure execution environment with a hosted computer are described. A host operating system of a computing system provides an encrypted checkpoint to a persistence module that executes in a secure execution environment of a hardware-protected memory area initialized by a security-enabled processor. The encrypted checkpoint is derived at least partly from another secure execution environment that is cryptographically certifiable as including another hardware-protected memory area established in an activation state to refrain from executing software not trusted by the client system.

Abstract: Implementations for providing a secure execution environment with a hosted computer are described. A security-enabled processor establishes a hardware-protected memory area with an activation state that executes only software identified by a client system. The hardware-protected memory area is inaccessible by code that executes outside the hardware-protected memory area. A certification is transmitted to the client system to indicate that the secure execution environment is established, in its activation state, with only the software identified by the request.

Abstract: Described herein are implementations for providing a platform adaptation layer that enables applications to execute inside a user-mode hardware-protected isolation container while utilizing host platform resources that reside outside of the isolation container. The platform adaptation layer facilitates a system service request interaction between the application and the host platform. As part of the facilitating, a secure services component of the platform adaptation layer performs a security-relevant action.

Abstract: A library operating system is employed in conjunction with an application in a virtual environment to facilitate dynamic application migration. An application executing in a virtual environment with a library operating system on a first machine can be suspended, and application state can be captured. Subsequently, the state can be restored and execution resumed on the first machine or a second machine.

Abstract: In one implementation, a computer-implemented method includes receiving, at a computer system, a request to solicit one or more users to generate media content for a campaign; identifying, by the computer system, a plurality of content creating users; obtaining demographic data for a plurality of content consuming users who have accessed the media content that was generated by the plurality of content creating users; determining distributions of the plurality of content consuming users across a plurality of demographic categories; selecting, by the computer system, a portion of the plurality of content creating users based on a comparison of i) the one or more parameters for the campaign and ii) the distributions of the plurality of content consuming users across the plurality of demographic categories; and providing information that identifies an opportunity to generate media content for the campaign.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: Described herein are implementations for providing a platform adaptation layer that enables applications to execute inside a user-mode hardware-protected isolation container while utilizing host platform resources that reside outside of the isolation container. The platform adaptation layer facilitates a system service request interaction between the application and the host platform. As part of the facilitating, a secure services component of the platform adaptation layer performs a security-relevant action.

Abstract: Implementations for providing a persistent secure execution environment with a hosted computer are described. A host operating system of a computing system provides an encrypted checkpoint to a persistence module that executes in a secure execution environment of a hardware-protected memory area initialized by a security-enabled processor. The encrypted checkpoint is derived at least partly from another secure execution environment that is cryptographically certifiable as including another hardware-protected memory area established in an activation state to refrain from executing software not trusted by the client system.

Abstract: Implementations for providing a secure execution environment with a hosted computer are described. A security-enabled processor establishes a hardware-protected memory area with an activation state that executes only software identified by a client system. The hardware-protected memory area is inaccessible by code that executes outside the hardware-protected memory area. A certification is transmitted to the client system to indicate that the secure execution environment is established, in its activation state, with only the software identified by the request.

Abstract: A library operating system is employed in conjunction with an application in a virtual environment to facilitate dynamic application migration. An application executing in a virtual environment with a library operating system on a first machine can be suspended, and application state can be captured. Subsequently, the state can be restored and execution resumed on the first machine or a second machine.

Abstract: The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.

Abstract: The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I?: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

Abstract: The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

Abstract: The invention is directed to thienopyrimidines and thienopyridines compounds of Formula I and Formula II: where R1, R3, B, Z, Q, p, q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3, the use of such compounds to reduce or inhibit kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.